Kenneth I. Moch joined Cognition Therapeutics in October 2016 as president and CEO. He has broad expertise building and leading private and public life science companies from start-up through commercialization, having served as president and CEO of Chimerix, Inc., Alteon, Inc., and Biocyte Corporation, where he pioneered the storage and therapeutic use of cord blood stem cells. He also co-founded The Liposome Company, Inc., a pioneer in liposomal delivery of anticancer and antifungal drugs, and served as a management consultant with McKinsey & Company.
Mr. Moch serves on the Governing Board of BIO, where he chairs the Organization’s Bioethics Committee and co-chairs the Emerging Companies Section Regulatory Policy Subcommittee. He is a founding member of the NYU Working Group on Compassionate Use and Pre-Approval Access. Mr. Moch holds an A.B. in biochemistry with a minor in health policy from Princeton University and an MBA from the Stanford University Graduate School of Business